Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis.

Li, Kang-Shuai; Guo, Sen; Chen, Yu-Xin; Zhang, Zong-Li

Li, Kang-Shuai; Guo, Sen; Chen, Yu-Xin; Zhang, Zong-Li.

Afiliação

Li KS; Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Guo S; Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Chen YX; Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zhang ZL; Department of General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Front Oncol ; 12: 1075685, 2022.

Article em En | MEDLINE | ID: mdl-36568193

Palavras-chave

Budd-Chiari syndrome; Hepatocellular carcinoma; IVC block; immunotherapeutic effect; malignancy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google